Literature DB >> 22624655

Anxiety and depression among AL amyloidosis patients: the role of cardiac symptoms.

Martina Smorti1, Francesco Cappelli, Franco Bergesio, Federico Perfetto.   

Abstract

UNLABELLED: Light-chain (AL) amyloidosis has the worst prognosis out of the different forms of cardiac amyloidosis, However, data are not available about the incidence of the disease-related psychological impact of AL amyloidosis in this population. In particular, no data are available about the impact of diagnosis communication or about the impact of cardiac symptom onset and severity on anxiety and depression levels among AL patients. AIM: To evaluate the role of time that has passed since the diagnosis was communicated, time that has passed since the onset of cardiac symptoms, and actual cardiac symptom severity have on level of anxiety, depression and psychological stress among cardiology patients with AL. Thirty-two AL patients with cardiac-related symptoms were administered General Health Questionnaire, State-Trait Anxiety Inventory and Centre for Epidemiological Study-Depression Scale. Clinical variables such as months gone by since diagnosis, months gone by since the onset of cardiac symptoms, and cardiac symptom severity (New York Heart Association (NYHA) class) were measured. Troponin, NT-pro BNP levels, Mayo Stage and echocardiographic characteristics were also collected.
RESULTS: According to questionnaire normative values, AL patients presented severe psychological distress, severe anxiety and clinical depression. Moreover, anxiety levels were determined by psychological distress (p < 0.001) and months gone by since the onset of cardiac symptoms (p < 0.01) while depression levels were influenced by NYHA class (p < 0.001).
CONCLUSIONS: Our results suggest that there is a need to plan psychological support for these patients with consideration for the onset of cardiac symptoms and symptom severity.

Entities:  

Mesh:

Year:  2012        PMID: 22624655     DOI: 10.3109/13506129.2012.687420

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  2 in total

1.  Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples.

Authors:  Michelle K White; Kristen L McCausland; Vaishali Sanchorawala; Spencer D Guthrie; Martha S Bayliss
Journal:  Patient Relat Outcome Meas       Date:  2017-12-07

2.  Content validation of the SF-36v2® health survey with AL amyloidosis patients.

Authors:  Michelle K White; Martha S Bayliss; Spencer D Guthrie; Kimberly P Raymond; Avery A Rizio; Kristen L McCausland
Journal:  J Patient Rep Outcomes       Date:  2017-12-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.